Compare PLSE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | IOVA |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | 975 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2015 | 2008 |
| Metric | PLSE | IOVA |
|---|---|---|
| Price | $23.02 | $3.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $22.00 | $9.00 |
| AVG Volume (30 Days) | 217.2K | ★ 13.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | $47.74 |
| Revenue Next Year | $287.54 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $1.64 |
| 52 Week High | $26.30 | $5.63 |
| Indicator | PLSE | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 44.48 |
| Support Level | $13.62 | $2.05 |
| Resistance Level | $23.42 | $4.33 |
| Average True Range (ATR) | 1.53 | 0.30 |
| MACD | 0.33 | -0.02 |
| Stochastic Oscillator | 71.51 | 22.44 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.